Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies: A simplified approach based on a single measurement 3 h p.i.

NuklearMedizin

Volumn 45, Issue 3, 2006, Pages 134-138

  Glatting, Gerhard ^a   Kull, T ^a   Blumstein, N M ^a   Bunjes, D ^a   Neumaier, B ^a   Buck, A K ^a   Reske, S N ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Anti CD66; Dosimetry; Radioimmunotherapy; Residence time; Treatment planning

Indexed keywords

ANTI CD66 MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; FEMALE; HUMAN; KIDNEY; LEUKEMIA; LIVER; MALE; MATHEMATICAL MODEL; RADIOIMMUNOTHERAPY; RESIDENTIAL CARE; RISK FACTOR; SCINTILLATION CAMERA; SPLEEN;

EID: 33745926810     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625927     Document Type: Article

References (22)

1. Alexander C, Holländer M, Schmidt W et al. Kinetics and Dosimetry of MAb-170: Evaluation of possibilities for intraperitoneal radioimmunotherapy. Nuklearmedizin 2001; 20: 207-14.
2. Buchmann I, Meyer RG, Herr W et al. Radioimmunotherapy for treatment of acute myeloid leukaemia and myelodysplastic syndrome: Conceptual changes. Nuklearmedizin 2005; 44: 107-17.
3. Bunjes D, Buchmann I, Duncker C et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001; 98: 565-72.
4. Dietlein M, Dressler J, Farahati J et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin 2004; 43: 115-20.
5. Fischer M, Behr T, Grünwald F et al. Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20(+) follicular B-cell non-Hodgkin's lymphoma. Nuklearmedizin 2004; 43: 171-6.
6. 111In-DOTA-TATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1257-62.
7. Glatting G, Landmarm M, Kull T et al. Internal radionuclide therapy: The UlmDos software for treatment planning. Med Phys 2005; 32: 2399-405.
8. 111Inpentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1386-92.
9. 86Y-DOTAO)-D-Phe1-Tyr3- octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30: 510-8.
10. 99mTc-labeled anti-NCA-95 MAbs. J Nucl Med 2000; 41: 531-7.
11. + in 2D mode. Cancer Biother Radiopharm 2004; 19: 482-90.
12. Reske SN, Gloeckner W, Schwarz A et al. Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet 1989; 2: 299-301.
13. Reske SN, Bunjes D, Buchmann I et al. Targeted bone marrow irradiation in the conditioning of high risk leukemia prior to stem cell transplantation. Eur J Nucl Med 2001; 28: 807-15.
14. Schneider P, Körber C, Körber-Hafner N et al. Does an individual estimation of half-life improve the results of radioiodine therapy of Graves' disease? Nuklearmedizin 2002; 41: 240-244.
15. Seitz U, Neumaier B, Glatting G et al. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. Eur J Nucl Med 1999; 26: 1265-73.
16. 131I-anti- B 1 antibody: Assessment of tumor dose-response. J Nucl Med 2003; 44: 260-8.
17. 90Y-Epratuzumab): Do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 2003; 44: 2000-18.
18. Siantar CH, Vetter K, DeNardo GL et al. Treatment planning for molecular targeted radionuclide therapy. Cancer Biother Radiopharm 2002; 17: 267-80.
19. Siegel JA, Thomas SR, Stubbs JB et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999; 40: 37-61S.
20. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46: 1023-7.
21. Strand SE, Jonsson BA, Ljungberg M et al. Radioimmunotherapy dosimetry-a review. Acta Oncol 1993; 32: 807-17.
22. Thomas SR. Options for radionuclide therapy: From fixed activity to patient-specific treatment planning. Cancer Biother Radiopharm 2002; 17: 71-82.